Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04348045
Title Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GERCOR - Multidisciplinary Oncology Cooperative Group
Indications

pancreatic adenocarcinoma

Therapies

Durvalumab + Selumetinib

Fluorouracil + Irinotecan + Leucovorin

Olaparib

Age Groups: adult | senior
Covered Countries


No variant requirements are available.